Cancer Drugs Approved Based on Biomarkers and Not Tumor Type—FDA Approval of Pembrolizumab for Mismatch Repair-Deficient Solid CancersVinay Prasad, Sham Mailankody, Victoria Kaestner|JAMA Oncology|2017Cited by 144